Digestery
Longevity supplements › NMN and Aging › Studies

Systematic review

Review of 147 animal and human studies of NAD+ boosters found mixed results

Braidy and colleagues · Experimental gerontology · 2020

Original title: NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Mixed

Most studies reported favourable results on age-related disorders. Evidence is limited and long-term human trials are few. Possible risks include toxic by-products, tumour growth and cell aging.

The study at a glance

Type of study
Systematic review
Who or what was studied
147 studies · Animal and human studies (113 preclinical, 34 clinical) of NAD+ raising
What was tested
NAM, NR, NMN, NAD+ and NADH vs control
What it measured
Several kinds of outcomes
Who has a stake
No disclosure in PubMed
No disclosure in PubMed.
Journal
Experimental gerontology, 2020
Source
PubMed record 31917996. This page is based on the abstract only.

How much this study counts

  • •Sums up 147 studies found with a set search method, without pooling the numbers.
  • •Measured several kinds of outcomes.
  • •The PubMed record has no conflict-of-interest statement.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

This paper is not on the ladder. It is a systematic review, and reviews and opinion pieces discuss studies that are already counted on the steps below.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    0

    Not done yet. This is the step that would answer the question.

  2. Trials in people: other measures

    9

    3 benefit, 2 mixed, 4 no difference

  3. Trials in people: lab tests or safety

    7

    4 benefit, 1 mixed, 2 no difference

  4. Population studies

    0

    None among the papers we read.

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    6

    5 benefit, 1 mixed

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does NMN slow aging?”

Not shown in people so far.

Confidence: very low. Based on 29 on-topic papers.

Read the full answer
  • Listed with the other papers, but not quoted in the page’s main findings.

Other reviews on this question

See all 29 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.